Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer

The potential for hepatic metastasis in nude mice was studied by the intrasplenic implantation method with five human pancreatic cancer cell lines, Capan-1, BxPC-3, AsPC-1, Panc-1, and MIAPaCa-2, especially in relation to serine protease expression, including urokinase-type plasminogen activator and...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 23; no. 12; p. 1669
Main Authors Ohta, T, Futagami, F, Arakawa, H, Tsukioka, Y, Kitagawa, H, Kayahara, M, Nagakawa, T, Miyazaki, I
Format Journal Article
LanguageJapanese
Published Japan 01.10.1996
Subjects
Animals
Gabexate - analogs & derivatives
Guanidines - pharmacology
Humans
Liver Neoplasms - prevention & control
Liver Neoplasms - secondary
Mice
Mice, Nude
Neoplasm Transplantation
Pancreatic Neoplasms - pathology
Protease Inhibitors - pharmacology
Tumor Cells, Cultured
Online AccessGet more information

Cover

More Information
Summary:The potential for hepatic metastasis in nude mice was studied by the intrasplenic implantation method with five human pancreatic cancer cell lines, Capan-1, BxPC-3, AsPC-1, Panc-1, and MIAPaCa-2, especially in relation to serine protease expression, including urokinase-type plasminogen activator and pancreatic trypsinogen 1 (cationic form). The inhibitory effect of a serine protease inhibitor agent, FOY-305, on hepatic metastasis was also a assessed. As a result, the potential for hepatic metastasis was well correlated with expression of pancreatic trypsinogen 1 in these cell lines, and the incidence of metastasis was significantly decreased by FOY-305. These findings suggest that pharmacologic inhibition of serine protease activity may be a new strategy for the therapy of pancreatic cancer metastasis.
ISSN:0385-0684